Sodium glucose cotransporter 2 inhibitors for all HFrEF patients: can we afford it? A cost-effectiveness analysis of dapagliflozin

Savarese G Lund LH. Global public health burden of heart failure. Card Fail Rev 2017; 3: 7–11. 2017/08/09. DOI: 10.15420/cfr.2016:25:2.

McMurray JJ Packer M Desai AS , et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993–1004. 2014/09/02. DOI: 10.1056/NEJMoa1409077.

Singh AK Singh R. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies. Expert Rev Clin Pharmacol 2019; 12: 299–308. 2019/03/01. DOI: 10.1080/17512433.2019.1588110.

McMurray JJV Solomon SD Inzucchi SE , et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995–2008. 2019/09/20. DOI: 10.1056/NEJMoa1911303.

Savira F Wang BH Kompa AR , et al. Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. Eur J Prev Cardiol. Epub ahead of print 2020. DOI: 10.1177/2047487320938272.

York Health Economics Consortium. Incremental Cost-Effectiveness Ratio (ICER) . 2016. https://yhec.co.uk/glossary/incremental-cost-effectiveness-ratio-icer/ (2016; accessed 24 June 2020).

Rawllins M. Health technology assessment. In: Bennett P Sharma P Brown MJ (eds) Clinical Pharmacology, 11th ed. London: Churchill Livingstone, 2012, pp. 55–61.

National Institute for Health and Care Excellence. Consultation paper – value-based assessment of health technologies. NICE. 2014. https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/VBA-TA-Methods-Guide-for-Consultation.pdf (2014; accessed 24 June 2020).

US Food and Drug Administration. FDA approves new treatment for a type of heart failure. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-type-heart-failure (2020; accessed 14 June 2020).